COMMUNIQUÉS West-GlobeNewswire

BioSyent Announces Normal Course Issuer Bid
04/12/2018
TORONTO, Dec. 04, 2018 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted the Company’s Notice of Intention to Make [...]
Caelum Biosciences Announces Two Oral Presentations of Additional Data from Phase 1b Study of Anti-Amyloid mAb CAEL-101 and Preclinical Imaging Study at 60th American Society of Hematology Annual Meeting
04/12/2018
Phase 1b data confirm efficacy in AL Amyloidosis with two cardiac markers correlated with survival Preclinical data demonstrate the potential of using radiolabeled CAEL-101 for real-time imaging of human amyloidosis in [...]
aTyr Pharma Announces Initiation of Phase 1b/2a Study of ATYR1923 in Patients with Pulmonary Sarcoidosis and Collaboration with the Foundation for Sarcoidosis Research (FSR)
04/12/2018
FSR Clinical Studies Network to assist with clinical site initiation to expedite patient enrollment SAN DIEGO, Dec. 04, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the [...]
Nu-Med Plus, Inc. President Helps Lead Call for New Innovation in Inhaled Nitric Oxide Industry
04/12/2018
Nu-Med Plus President Jeff Robins published an open letter calling for greater awareness of inhaled nitric oxide to potentially advance treatment options for malaria, COPD, tuberculosis and ARDS SALT LAKE CITY, Dec. 04 [...]
Progressive Care Inc. Garners International News Coverage in Leading Trade Publications for Its Efforts to Improve Adherence
04/12/2018
MIAMI, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Progressive Care Inc. ( OTCQB: RXMD ), a personalized healthcare services and technology company, today announced that it has garnered notable international media coverage in top [...]
BrainStorm Cell Therapeutics to Present at the 29th International Symposium on ALS/MND
04/12/2018
Poster highlights enrichment strategies for clinical trials in ALS NEW YORK, Dec. 04, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem [...]
Arch Therapeutics Announces Positive Outcome of Ruling from Japanese Intellectual Property High Court
04/12/2018
Massachusetts Institute of Technology and Versitech Limited patent, licensed exclusively by Arch, is maintained without amendment as prior lower court decision is affirmed. FRAMINGHAM, Mass., Dec. 04, 2018 (GLOBE [...]
Moleculin Announces Breakthrough Discovery for its WP1066
04/12/2018
WP1066 shown to counteract resistance to checkpoint blockades HOUSTON, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company [...]
OpGen Receives Regulatory Approval to Market Pathogen Identification Products in Colombia
04/12/2018
Approval gives OpGen its first commercial product in the region; paves way for broader expansion into South American markets GAITHERSBURG, Md., Dec. 04, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced [...]
Marinus Pharmaceuticals Phase 2 Clinical Trial Data Show Long-term Effectiveness of Ganaxolone in Reducing Seizure Frequency in CDKL5 Deficiency Disorder Patients
04/12/2018
Predictive biomarker also identified in PCDH19-related pediatric epilepsy RADNOR, Pa., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical [...]
TG Therapeutics, Inc. Announces Follow-Up Data from the Triple Combination of Ublituximab, Umbralisib, and Bendamustine in Patients with DLBCL and FL at 60th American Society of Hematology Annual Meeting and Exposition
04/12/2018
NEW YORK, Dec. 04, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced updated clinical data from its Phase I/Ib trial of ublituximab (TG-1101), the Company’s novel glycoengineered anti-CD20 [...]
Dermira Enters into Credit Facility with Athyrium Capital Management
04/12/2018
Facility provides additional financial flexibility in connection with ongoing QBREXZA launch and lebrikizumab program MENLO PARK, Calif., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a [...]
Lenzilumab Data Presented in Oral Presentation at the American Society of Hematology (ASH)
04/12/2018
Lenzilumab (an anti-GM-CSF antibody) in combination with CAR-T cell therapy prevents cytokine release syndrome and neuroinflammation while improving durable control of leukemic disease Exponential increase in T cell [...]
ExCellThera announces results of clinical trial using ECT-001 for blood cancers
04/12/2018
MONTREAL, Dec. 04, 2018 (GLOBE NEWSWIRE) -- ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, today announced results from [...]
Tetra Bio-Pharma Convenes First National Medical Advisory Board
04/12/2018
Key Opinion Leaders Weigh in on Scientific Research in Cannabinoids ORLEANS, Ontario, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc (“ Tetra ” or “ TBP ”), (TSX VENTURE: TBP) (OTCQB: TBPMF), – announced that it [...]
ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients
04/12/2018
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the [...]
Emerald Joint Venture Receives Licenses from Health Canada to Sell Proprietary Products Supporting the Endocannabinoid System
04/12/2018
Endo Brain recently awarded 2018 SupplySide Editor’s Choice Award for Brain Health Planned mid-2019 product launch will open natural health product, grocery, and pharmacy store channels to Emerald non-cannabis product [...]
Pluristem Therapeutics Enters into Cell Thawing Device License Agreement with Chart Industries, Inc.
04/12/2018
HAIFA, Israel, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that [...]
Preliminary Results from Randomized Phase 2 Trial Demonstrate Trilaciclib Improved Progression-Free Survival in Combination with Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer
04/12/2018
Patients on trilaciclib received more chemotherapy cycles than those in the control arm Trilaciclib showed multi-lineage myelopreservation benefits when adjusting for longer duration of treatment Safety profile [...]

Pages